Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) will report fourth quarter and full year 2025 financial results and provide a business update on March 2, 2026 at 4:30 p.m. ET. The company will host a conference call and live webcast; registration and replay will be available on Nuvation Bio's Investor Relations website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – NUVB
On the day this news was published, NUVB gained 1.91%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NUVB slipped 0.35% with light volume, while close biotech peers (ELVN, ORIC, GPCR, RCUS, ZYME) showed larger declines between about 2–6%, indicating broader biotech softness but a comparatively resilient NUVB move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Trial upgrade | Positive | -1.1% | Phase 2 SIGMA trial converted to pivotal Phase 3 with larger enrollment. |
| Jan 12 | Prelim earnings | Positive | -19.6% | Preliminary 4Q25/2025 results, IBTROZI revenue, cash and 2026 outlook shared. |
| Jan 12 | Licensing deal | Positive | -19.6% | Eisai taletrectinib licensing with upfront, milestones and tiered royalties. |
| Jan 06 | Conference invite | Neutral | +4.1% | J.P. Morgan Healthcare Conference presentation and webcast details announced. |
| Dec 06 | NRDL inclusion | Positive | +0.3% | Seven innovative drugs included in China’s 2025 NRDL effective Jan 2026. |
Recent history shows multiple positive strategic and clinical updates followed by negative price reactions, indicating a tendency for the stock to sell off or fade on good news.
Over the past few months, Nuvation Bio has announced several significant developments. In January 2026, it reported preliminary 4Q25/2025 results with IBTROZI revenue, a $25M milestone, and a cash balance of about $529.2M, alongside an Eisai licensing deal worth up to €195M. On February 9, 2026, it converted the SIGMA (G203) trial of safusidenib into a pivotal Phase 3 study with expanded enrollment. Despite these seemingly positive catalysts, several of these announcements were followed by share price declines, framing today’s simple earnings-date notice against a backdrop of prior news-driven volatility.
Market Pulse Summary
This announcement simply schedules Nuvation Bio’s fourth-quarter and full-year 2025 results call for March 2, 2026. Ahead of that event, recent history includes a pivotal Phase 3 safusidenib trial upgrade and an Eisai licensing deal with meaningful milestones and royalties. At the same time, the stock trades well below its 52-week high and insider activity reflects net selling. Investors may focus on updated revenue trends, cash runway details, and progress across key pipeline programs during the call.
AI-generated analysis. Not financial advice.
Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI ®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-868, a BD2-selective BET inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-2-2026-302688141.html
SOURCE Nuvation Bio Inc.
FAQ
When will Nuvation Bio (NUVB) report Q4 and full-year 2025 results?
How can investors access the NUVB conference call and webcast on March 2, 2026?
Will Nuvation Bio (NUVB) provide a replay of the March 2, 2026 webcast?
What topics will Nuvation Bio (NUVB) cover in the March 2, 2026 call?
Is registration required to listen to Nuvation Bio (NUVB) live webcast on March 2, 2026?
